[Focus on the screening for prostate cancer by PSA]

Area of Science:

• Urology
• Oncology
• Biomarker Research

Context:

• Prostate cancer detection relies on PSA serum levels and digital rectal exams, leading to increased incidence but lower mortality in developed nations.
• Routine PSA screening recommendations are debated, with some advising against it due to overdiagnosis and overtreatment concerns.
• Existing methods have unsatisfactory accuracy, necessitating improved diagnostic strategies.

Purpose:

• To evaluate novel biomarkers for enhancing prostate cancer detection accuracy.
• To identify more reliable predictors of prostate cancer than traditional PSA testing, particularly in the 2-10 ng/ml range.
• To reduce overdiagnosis and overtreatment associated with current prostate cancer screening protocols.

Summary:

• Prostate health index (phi) and PCA3 are investigated as advanced markers for prostate cancer detection.
• These novel markers demonstrate superior accuracy compared to total PSA and percentage free PSA in predicting prostate cancer at initial biopsy.
• Specifically, in patients with total PSA levels between 2-10 ng/ml, phi and PCA3 are the strongest predictors.

Impact:

• Improved pre-biopsy prostate cancer detection rates.
• Potential to significantly reduce prostate cancer overdiagnosis and subsequent overtreatment.
• Enhanced shared decision-making between clinicians and patients regarding screening and treatment options.